Literature DB >> 18351462

Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction.

Subhas C Biswas1, Jean Buteau, Lloyd A Greene.   

Abstract

Glucagon-like peptide-1 (GLP-1) is a glucoincretin hormone most intensively studied for its actions on insulin secreting beta-cells. GLP-1 and its receptor are also found in brain and accumulating evidence indicates that GLP-1 has neuroprotective actions. Here, we investigated whether GLP-1 protects neuronal cells from death evoked by nerve growth factor (NGF) withdrawal. Compromised trophic factor signaling may underlie neurodegenerative diseases ranging from Alzheimer disease to diabetic neuropathies. We report that GLP-1 provides sustained protection of cultured neuronal PC12 cells and sympathetic neurons from degeneration and death caused by NGF deprivation. Past work shows that NGF deprivation induces the pro-apoptotic protein Bim which contributes to neuron death. Here, we find that GLP-1 suppresses Bim induction promoted by NGF deprivation. Thus, GLP-1 may protect neurons, at least in part, by suppressing Bim induction. Our findings support the idea that drugs that mimic or elevate GLP-1 represent potential therapeutics for neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18351462     DOI: 10.1007/s11064-008-9646-4

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  47 in total

1.  Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat.

Authors:  P J Larsen; M Tang-Christensen; D S Jessop
Journal:  Endocrinology       Date:  1997-10       Impact factor: 4.736

Review 2.  Cell cycle molecules define a pathway required for neuron death in development and disease.

Authors:  Lloyd A Greene; David X Liu; Carol M Troy; Subhas C Biswas
Journal:  Biochim Biophys Acta       Date:  2006-12-13

3.  Bim is elevated in Alzheimer's disease neurons and is required for beta-amyloid-induced neuronal apoptosis.

Authors:  Subhas C Biswas; Yijie Shi; Jean-Paul G Vonsattel; Conrad L Leung; Carol M Troy; Lloyd A Greene
Journal:  J Neurosci       Date:  2007-01-24       Impact factor: 6.167

4.  Cellular localization of proglucagon/glucagon-like peptide I messenger RNAs in rat brain.

Authors:  V K Han; M A Hynes; C Jin; A C Towle; J M Lauder; P K Lund
Journal:  J Neurosci Res       Date:  1986       Impact factor: 4.164

5.  Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation.

Authors:  Subhas C Biswas; Lloyd A Greene
Journal:  J Biol Chem       Date:  2002-10-17       Impact factor: 5.157

Review 6.  Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

Authors:  Michael A Nauck; Juris J Meier
Journal:  Regul Pept       Date:  2005-06-15

Review 7.  Neuronal structure is altered by amyloid plaques.

Authors:  Tara L Spires; Bradley T Hyman
Journal:  Rev Neurosci       Date:  2004       Impact factor: 4.353

8.  cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells.

Authors:  G Kang; O G Chepurny; G G Holz
Journal:  J Physiol       Date:  2001-10-15       Impact factor: 5.182

9.  Glucagon-like peptide-1 prevents beta cell glucolipotoxicity.

Authors:  J Buteau; W El-Assaad; C J Rhodes; L Rosenberg; E Joly; M Prentki
Journal:  Diabetologia       Date:  2004-04-17       Impact factor: 10.122

10.  FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons.

Authors:  Jonathan Gilley; Paul J Coffer; Jonathan Ham
Journal:  J Cell Biol       Date:  2003-08-11       Impact factor: 10.539

View more
  15 in total

Review 1.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

Review 2.  DPP-4 inhibitors: a promising therapeutic approach against Alzheimer's disease.

Authors:  Efthalia Angelopoulou; Christina Piperi
Journal:  Ann Transl Med       Date:  2018-06

3.  Exendin-4 protects Aβ(1-42) oligomer-induced PC12 cell apoptosis.

Authors:  Chen Qiu; Yan-Ping Wang; Xiao-Dong Pan; Xiao-Ying Liu; Zhou Chen; Li-Bin Liu
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

4.  Early intranasal insulin therapy halts progression of neurodegeneration: progress in Alzheimer's disease therapeutics.

Authors:  Suzanne M de la Monte
Journal:  Aging health       Date:  2012

Review 5.  Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders.

Authors:  Isidro Salcedo; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 6.  Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders.

Authors:  Huan Cai; Wei-na Cong; Sunggoan Ji; Sarah Rothman; Stuart Maudsley; Bronwen Martin
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

Review 7.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

8.  Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway.

Authors:  Jian-Hui Liu; Fei Yin; Li-Xia Guo; Xiao-Hong Deng; Yin-He Hu
Journal:  Acta Pharmacol Sin       Date:  2009-01-19       Impact factor: 6.150

Review 9.  Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Drugs       Date:  2012-01-01       Impact factor: 9.546

Review 10.  Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.